GLP-3

• GLP-3 is a synthetic peptide analogue acting on three receptors at once.
• It combines GLP-1, GIP and glucagon receptor agonism in a single molecule.
• It belongs to the incretin analogues, a generation newer than the dual agonists.
• Supplied as a lyophilised powder for reconstitution.

• Published work describes simultaneous activation of three receptor pathways involved in the regulation of energy intake and glycaemia.
• GLP-1 agonism is associated in the literature with slowed gastric emptying and satiety signalling.
• Engagement of the glucagon receptor is studied in connection with energy expenditure — this is the main difference from the dual agonists.
• How much each pathway contributes to the outcome is the subject of ongoing research.

• Energy balance and the regulation of food intake.
• Glycaemic control and insulin signalling.
• Lipid metabolism.
• Comparative studies against single and dual incretin analogues.

GLP-3 is under active clinical investigation and, at the time of writing, development for every indication being studied is still under way. The available data come from clinical trials run by the manufacturer and from published literature, and apply to the conditions they come from.

GLP-3 is a pharmacologically active substance with the character of a drug substance. This item is a reference standard intended strictly for laboratory and research use. It is not a medicine, it is not authorised for administration to humans, and it must not be used for diagnosis, prevention or treatment. We provide no dosing, protocols or health advice. The purchaser is responsible for complying with the law in force at the place of delivery and for safe handling in line with laboratory practice.